Current GLP-1 Cash-Pay Pricing is $149 to $449 per month directly from the manufacturer with a prescription.

Prices for GLP-1 medications are changing and becoming more transparent.

Both Novo Nordisk and Eli Lilly are now offering direct-to-consumer cash pricing programs for patients who do not have insurance coverage for GLP-1 medications.

This is a major shift and an important one for navigating affordability.

Let’s break down the most current options available and what truly matters beyond price.

Why This Matters

Historically, GLP-1 medications came with list prices over $1,000/month, making them inaccessible for many patients.

Now, pharmaceutical companies are:

• Offering transparent cash pricing
• Selling through manufacturer-backed programs
• Competing with each other which is helping bring costs down

These programs are not compounding pharmacies; they are brand-name medications directly from the manufacturers.

A Quick (Important) Reality Check

We’ve had many patients come to us saying:

“I found a company offering this medication for a lower cash price than the pharmacy.”

Here’s what we’re seeing in real time – 

In many cases, those prices are not actually lower.

They are often:

• The same manufacturer-set cash price
• Routed through a third-party company
• Sometimes bundled with extra membership or service fees

In other words, many of these offers are not true discounts; they are simply the same pricing from Novo Nordisk or Eli Lilly, repackaged.

This is why understanding where your medication is coming from is just as important as the price itself.

Novo Norodisk makes Wegovy (semaglutide)

Injectable Wegovy (semaglutide) standard doses 0.25mg to 2.4mg weekly

• The introductory offer is $199/month for new prescriptions
• Then $349/month for all doses up to 2.4mg 

NEW: Injectable Wegovy (semaglutide) high dose 7.2mg weekly

• $399/month 

• This higher-dose option is for patients that have been on Wegovy (semaglutide) 2.4mg weekly for at least 4 weeks and need a higher dose 

NEW: Oral Wegovy (semaglutide, peptide GLP-1) 1.5mg to 25mg

• Starting at $149/month for the 1.5mg and 4mg doses
• Then $299/month for the 9mg and 25mg doses 

Eli Lilly makes Zepbound (tirzepatide) and Foundayo (orforglipron)

Injectable Zepbound Kwikpen or vials (tirzepatide, dual GLP-1 and GIP)

• Starting dose of 2.5mg is ~$299/month

• Mid-range doses are ~$399/month

• Higher doses are ~$449/month+

NEW: Oral Foundayo (orforglipron, small molecule GLP-1) 

• Starting dose of 0.8mg is ~$149/month
• Higher doses are ~$299/mo

What Matters Just as Much as Price: Medical Guidance

While pricing is finally becoming more accessible, there’s something equally if not more important:

Who is guiding your care?

GLP-1 medications are powerful tools, but they are not “one-size-fits-all.”

Working with a provider who is trained in obesity medicine ideally a board-certified obesity physician through organizations like the American Board of Obesity Medicine ensures that your care is:

• Personalized to your medical history
• Adjusted based on your response and side effects
• Aligned with your long-term health goals—not just short-term weight loss

The Importance of Shared Decision-Making

The best outcomes don’t come from simply being prescribed medication.

They come from collaborative, informed decision-making between you and your provider.

This includes:

• Choosing the right medication (semaglutide vs tirzepatide AND oral vs injectable options)
• Selecting the appropriate dose and timing
• Monitoring:
• Nutrition
• Muscle mass
• Metabolic health
• Adjusting your plan as your body responds

Because your journey is not just about weight it’s about:

• Energy
• Strength
• Longevity
• Overall quality of life

What Patients Should Take Away

1. These are manufacturer-direct prices

Set by Novo Nordisk and Eli Lilly for:

• FDA-approved medications
• Cash-paying patients without coverage

2. Not all “offers” are truly different

If you’re seeing programs online, ask:

Is this actually cheaper or just the same price through a middleman?

3. Access is improving but guidance matters

• New pricing: ~$149–$449/month

• More options than ever before

But medication alone is not a complete plan.

The Bigger Picture

We are entering a new phase in obesity medicine where:

• Access is improving
• Options are expanding
• Pricing is becoming more transparent

But success still depends on:

The right treatment + the right guidance + the right plan for you

Final Thoughts

If you’ve previously been told these medications were out of reach financially, it may be time to revisit that conversation.

Just remember:

• The best price often comes directly from the manufacturer
• The best outcomes come from personalized, physician-guided care

Because in the end, this isn’t just about access to medication

It’s about having a plan that is safe, effective, and built specifically for you.

For more information or updates on pricing and offers, please visit the following pharmacy websites:

Lily Direct Self Pay

NovoCare Self Pay